Latest Levetiracetam Stories
DALLAS, March 4, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Epilepsy - Pipeline Review, H1 2015" therapeutic market research report of 330 pages with latest updates,
-- Primary efficacy and safety data from the largest Phase 3 brivaracetam study involving 768 patients presented at the 68th Annual Meeting of the American Epilepsy Society BRUSSELS, Dec.
- 24 UCB-sponsored presentations including new data on VIMPAT® (lacosamide) BRUSSELS, Dec.
RnRMarketResearch.com adds “Partial Seizure – Pipeline Review, H2 2014” to its store.
MarketOptimizer.org adds “PharmaPoint Epilepsy – Global Drug Forecast and Market Analysis to 2022 – Event-Driven Update” to its store.
Transparency Market Research added a new report "Global Epilepsy Therapeutics Market: Industry Analysis, Size, Share, Growth and Forecast 2019" to its report store.
MISSISSAUGA, ON, July 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc.
A new study finds that the epilepsy drug levetiracetam appears not to be associated with thinking, movement and language problems for preschool children born to mothers who took the drug during pregnancy, although the drug valproate was associated with some difficulties in preschoolers.